Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q2 FY25 Earnings Presentation
18 slides from Zim Laboratories's earnings presentation, Nov 9, 2024
Slide 1: Regulation 30 cover letter to BSE and NSE
Ref No.: ZLL/CS/BSE/NSE Date: 09.11.2024 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLAB) D
Slide 2: Q2 & H1FY25 – Earnings Presentation
ZIM LABORATORIES LIMITED Q2 & H1FY25 – EARNINGS PRESENTATION
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: Content
CONTENT 01 BUSINESS MODEL 02 KEY HIGHLIGHTS – H1FY25 03 BUSINESS MIX 04 R&D & INNOVATION 05 SHAREHOLDING 3
Slide 5: Integrated Business Model
INTEGRATED BUSINESS MODEL Business Distinct Offerings End-to-End Product Development Mix Across therapy segments and Dosage forms Offerings Therapy Segments Conceptualisation involves R&D Tablets Anti - Infective 01. Product Conceptualisation Export o FF and product research to examine feasibility o
Slide 6: Key Highlights – H1FY25
KEY HIGHLIGHTS – H1FY25 Financial Highlights Business Highlights Total Operating Income increased ZIM filed 1 Gastrointestinal NIP 13.6% YoY; ₹1,740 Mn in H1FY25 through DCP process in 5 EU vs ₹1,532 Mn in H1FY24 countries EBITDA increased to ₹199 Mn in During H1, ZIM filed 1 NIP & 1 H1FY25 vs ₹166
Slide 7: Financial Performance – H1FY25
FINANCIAL PERFORMANCE – H1FY25 Total Operating Income (₹ Mn) EBITDA (₹ Mn) & EBITDA margin Profit After Tax (PAT) (₹ Mn) & PAT margin 2.8% 1.9% 10.8% 11.4% 1,740 199 43 166 33 1,532 H1FY24 H1FY25 H1FY24 H1FY25 H1FY24 H1FY25 o Total Operating Income for H1FY25 grew 13.6% YoY, driven by continued incr
Slide 8: Financial Performance – Q2FY25
FINANCIAL PERFORMANCE – Q2FY25 Total Operating Income (₹ Mn) EBITDA (₹ Mn) & EBITDA margin Profit After Tax (PAT) (₹ Mn) & PAT margin 12.5% 11.0% 11.8% 4.8% 1.1% 2.6% 922 107 109 41 858 90 818 24 9 Q2FY24 Q1FY25 Q2FY25 Q2FY24 Q1FY25 Q2FY25 Q2FY24 Q1FY25 Q2FY25 o Total Operating Income grew 7.4% YoY
Slide 9: Business Mix
BUSINESS MIX Pharma Revenue (₹ Mn) & Contribution to Total Nutra Revenue (₹ Mn) & Contribution to Total Operating Income (%) Operating Income (%) 33% 86% 83% 29% 80% 74% 26% 71% 67% 20% 17% 14% 978 255 266 268 740 708 201 654 540 552 134 118 Q1FY24 Q2FY24 Q3 Q4 Q1FY25 Q2 Q1FY24 Q2 Q3 Q4 Q1FY25 Q2 o
Slide 10: Revenue Mix
REVENUE MIX Q2FY24 Q2FY25 H1FY24 H1FY25 55, 6% 27, 3% 101, 7% 59, 4% 137, 15% 214, 14% 214, 12% 125, 15% 678, 79% 1,217, 758, 82% 79% 1,467, 84% Numbers in ₹Mn Export India Deemed Export o Q2FY25 : Export business grew 11.8% YoY reaching ₹758 Mn in Q2FY25 vs ₹678 Mn in Q2FY24 o H1FY25 : Export busin
Slide 11: Innovative Product Contribution
INNOVATIVE PRODUCT CONTRIBUTION NIP Revenue (₹ Mn) & Contribution to Total OTF Revenue (₹ Mn) and Contribution to Total Operating Income (%) Operating Income (%) 18.6% 12.9% 4.9% 4.3% 8.4% 152 6.9% 6.2% 119 5.1% 3.4% 3.4% 3.3% 3.1% 72 73 45 37 39 47 49 33 23 26 Q1FY24 Q2 Q3 Q4 Q1FY25 Q2 Q1FY24 Q2 Q3
Slide 12: R&D Driving Product Innovation
R&D DRIVING PRODUCT INNOVATION R&D Expense Mix % of Total R&D Investment 86 2 73 Total R&D Spend as % 37% 23% of Total Operating Income 9.7% R&D Team Post- Capital Expenses on BE PhDs 11% Size Graduates study, registrations etc 2% 8.7% Capital Expenses on 6 4 ₹168 Mn Infrastructure & Equipment Inves
Slide 13: Income Statement
INCOME STATEMENT Particulars (₹ Mn) Q2FY25 Q2FY24 YoY % H1FY25 H1FY24 YoY % Total Operating Income 922 858 7.4% 1,740 1,532 13.6% Other Income 13 14 (7.1%) 23 25 (8.0%) Total Income 935 872 7.2% 1,763 1,557 13.2% EBITDA 109 107 1.9% 199 166 19.9% EBITDA % 11.8% 12.5% (70 bps) 11.4% 10.8% 60bps Profi
Slide 14: Balance Sheet
BALANCE SHEET Particulars (₹ Mn) H1FY25 FY24 FY23 FY22 Gross Block – Tangible & Intangible Assets including WIP 3,326 3,089 2,257 1,920 Net Block – Tangible & Intangible Assets including WIP 2,261 2,031 1,357 1,174 Other Non- Current Assets 97 161 150 121 Current Assets 1,916 2,276 1,909 2,121 Total
Slide 15: Key Financials
KEY FINANCIALS Gross & Net Fixed Assets (₹ Mn) Gross Current Assets (GCA) as % of Total Assets 62% 3,326 56% 3,089 51% 45% 2,257 2,261 1,920 2,031 1,174 1,357 FY22 FY23 FY24 H1FY25 FY22 FY23 FY24 H1FY25 Gross Fixed Assets Net Fixed Assets % of Total Assets Net Worth (₹ Mn) Total Borrowing (₹ Mn) & G
Slide 16: Shareholding
SHAREHOLDING Ownership % (September 2024) Traded Volume (In K) BSE+NSE 40,248 33% 26,593 42% 15,997 13,089 14,093 7% Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 5% 13% • Number of Shareholders at end of Q2FY25 accounted to 17.3K Promoter Body corporates NRI & Foreign Individuals HNI • The company is seeing g
Slide 17: Share Price Movement
SHARE PRICE MOVEMENT ZIM (BSE) vs BSE S&P Healthcare Index ZIM (NSE) vs Nifty Healthcare Index 14,604 43,895 13,988 41,459 13,138 38,689 12,380 11,837 11,989 36,541 35,079 35,053 35,232 35,328 33,816 11,000 9,487 9,865 10,350 31549 30375 9, 622 28194 27272 123 123 117 115 115 117 115 115 113 112 112
Slide 18: Thank You
THANK YOU INVESTOR RELA TI ONS ZIM’s Investor Relations Mr. Zain Daud zain.daud@zimlab.in M: +91 9022434631 GoIndia Advisors – IR Firm Ms. Sheetal Khanduja Ms. Deepika Sharma Ms. Priya Sen sheetal@goindiaadvisors.com deepika@goindiaadvisors.com priya@goindiaadvisors.com M:+91 9769364166 M:+91 845102